NVCR: Growth in oncology franchises and global expansion drive profitability and pipeline momentum
Disciplined investment and cost controls have reignited GBM growth and enabled global expansion, with strong launches in pancreatic and lung cancer, especially in Japan. Profitability is within reach, and clinical trials are advancing, including new combination strategies with KRAS inhibitors.Based…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.